Cormorant Asset Management, LP Aveo Pharmaceuticals, Inc. Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$5.12 - $6.89 $4.57 Million - $6.16 Million	-893,500 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.21 - $7.45 $3.77 Million - $4.52 Million	-606,500 Reduced 40.43%	893,500 $5.89 Million
Q1 2021 May 17, 2021	BUY	$5.97 - $15.28 $8.96 Million - $22.9 Million	1,500,000 New	1,500,000 $11 Million
Q4 2020 Feb 16, 2021	SELL	$5.08 - $6.68 $5.08 Million - $6.68 Million	-1,000,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$4.16 - $6.26 $1.46 Million - $2.19 Million	-350,000 Reduced 25.93%	1,000,000 $5.94 Million
Q2 2020 Aug 14, 2020	BUY	$3.47 - $9.99 $4.68 Million - $13.5 Million	1,350,000 New	1,350,000 $6.95 Million

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.